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Abstract
Objectives: We previously reported a correlation between levels of microparticles carrying CD31 (PMP CD31+) and
disease activity in MS. However, the effects of long term (12 month) treatment with high dose, high frequency
interferon-b1a (Rebif™) on plasma levels of PMPCD31+, PMPCD146+, and PMPCD54+ and MRI measures of disease
activity have not yet been assessed.
Methods: During this prospective 1-year study, we used flow cytometry to measure changes in plasma
microparticles (PMP) bearing CD31 (PMPCD31+), CD146 (PMPCD146+), and CD54/ICAM-1 (PMPCD54+) in 16 consecutive
patients with relapsing-remitting MS (RRMS) before and after 3, 6, and 12 months of subcutaneous therapy with
interferon-beta1a (44 micrograms, 3X weekly). At each visit, clinical exams and expanded disability status scale
(EDSS) scores were recorded.
Results: Plasma levels of PMPCD31+, and PMPCD54+ were significantly reduced by treatment with IFN-b1a. PMPCD146
+ appeared to decrease only at 3 months and did not persist at 6 and 12 months (p = 0.0511). In addition, the
decrease in plasma levels of PMPCD31+ and PMPCD54+ levels at 12 months were associated with a significant
decrease in the number and volume of contrast enhancing T1-weigthed lesions.
Conclusion: Our data suggest that serial measurement of plasma microparticles (PMP), particularly in the initial
stages of MS (when neuro-inflammatory cascades are more intense), may serve as reliable and reproducible
surrogate markers of response to IFN-b1a therapy for MS. In addition, the progressive decline in plasma levels of
PMPCD31+ and PMPCD54+ further supports the concept that IFN-b1a exerts stabilizing effect on the cerebral
endothelial cells during pathogenesis of MS.
Introduction
Multiple sclerosis (MS) is an immune-mediated neurode-
generative disease of the human central nervous system
(CNS) characterized clinically by a relapsing-remitting
course. Neuropathologically MS manifests with develop-
ment of demyelinating lesions which affect both gray and
white matter [1,2] disruption of the blood brain barrier
(BBB) and transendothelial migration of lymphocytes and
macrophages across inflamed CNS endothelial mono-
layers appear to be among the earliest CNS and spinal
cord abnormalities in MS [3]. Activation of the cerebral
endothelial cells and their binding with activated leuko-
cytes are early crucial steps in creation of MS demyelinat-
ing lesions produced by immune cells [4,5].
Cerebral endothelial cells, the main components of the
BBB, contain tight and adherens junctions which create
a highly impenetrable and impermeable anatomic-phy-
siologic barrier against circulating plasma neurotrans-
mitters, cytokines, formed blood elements and soluble
and insoluble molecular components of the circulating
blood. Upon activation by pro-inflammatory cytokines
such as IFN-g or TNF-a, released by activated T-lym-
phocytes, endothelial cells shed small fragments of their
membranes, known as endothelial microparticles (PMP)
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[6]. These fragments contain some of the surface adhe-
sion molecules and other endothelial markers of their
parent cells [7], including, but not limited to, platelet-
endothelial cell adhesion molecule (PECAM-1/CD31),
human endothelial marker CD146, and intercellular
adhesion molecule (ICAM-1/CD54). Therefore while it
is difficult to evaluate inflammatory endothelial markers
in MS in situ, microparticles may provide a remote
‘snapshot’ of the surface of inflamed endothelium and
provide information on the extent of platelet and leuko-
cyte activity in MS.
We previously reported elevated plasma levels of PMP
in MS patients and demonstrated that the plasma levels of
PMPCD31+ may reflect acute endothelial injury with posi-
tive association with presence of contrast enhancing
lesions [3]. Additionally, we reported that various sub-spe-
cies of PMP form complex with different leukocytes and
by formation of such complexes, they promote the inflam-
matory process by facilitating transendothelial migration
of the leukocytes [6]. In the current study, we hypothe-
sized that prospective serial measurement of three sub-
species of PMP CD31+, PMPCD146+, and PMPCD54+ may
reflect disease activity and serve as a surrogate marker of
therapeutic response to high dose, high frequency inter-
feron-b1a. We also assessed the correlation among these
sub-species of PMP and MRI parameters.
Methods
During this one year prospective study, a cohort of 16
patients who met the Poser et al. criteria [8] for clini-
cally definite MS, were studied. The clinical study was
approved by Louisiana State University Health Sciences
Center-institutional review board and all patients pro-
vided informed consent. For at least three months prior
to initiation of treatment with IFN-b1a, none of the sub-
jects had received any immunosuppressive treatment or
corticosteroids. All study subjects underwent neurologi-
cal examination at the study entry prior to initiation of
treatment with IFN-b1a and at 3, 6, and 12 months
after initiation of treatment. At each visit, their
expanded disability status scale (EDSS) scores were
determined. Peripheral venous blood specimens (base-
line) were collected prior to initiation and within the
first 15 hours of treatment with IFN-b1a and at months
3, 6, and 12 after treatment initiation. The study sub-
jects were treated with IFN-b1a 44 micrograms ug sub-
cutaneously three times weekly. Because therapy cannot
be withheld from MS patients, this study did not con-
tain an arm consisting of untreated MS patients.
Measurement of PMP using flow cytometry
Using a 21 gauge needle, venous blood was obtained in
citrate loaded vacutainer tubes. Measurements of plasma
PMP were performed within four hours from specimen
collection. Briefly, blood specimen was centrifuged at
160 × g for 10 minutes to prepare platelet rich plasma
(PRP). Next, the PRP specimen was centrifuged for 6
minutes at 1500 × g to generate platelet poor plasma
(PPP). Then, each 25 μl aliquot of PPP was incubated
with 2 μl of anti-CD31-PE, 2 μl of anti-CD146, and 2 μl
of anti-CD54 at ambient temperature for 20 minutes
with gentle shaking (80 rpm). The PMPs in the sample
were measured using a Beckman Coulter FC500 MCL
flow cytometer system equipped with CXP software
(Beckman Coulter, Miami, FL). The sample flow rate
and particle detection settings are identical to that
described previously [3]. Data collection is based on
both multi-parameter and uni-parameter analyses of
PMPCD31+, PMPCD146+, and PMPCD54+. To evaluate the
possibility that leukocyte adhesion of microparticles
might be measured, the anti-leukocyte common antigen
CD45 was used in the cocktails. With the exception of
whole blood analysis (used as a positive control) negligi-
ble CD45+ events were detected in the PPP
preparations.
Statistical analysis
Data were analyzed using Instat (Graphpad software, La
Jolla CA) using repeated measures analysis of variance
with Dunnett’s post-testing to determine time points
which differed statistically from starting baseline values.
Data are shown as the average ± standard error. Statisti-
cal differences in contrast enhancing T1-weighted lesion
volumes at t = 0 were compared with t = 12 months
using two tailed unpaired students t-test. Microparticle
data are shown from t = 0 to 12 months. PMP counts
and volumes of contrast enhancing T1-weighted data
are also plotted bi-directionally to show separate non-
overlapped groupings for PMPCD54+ (ICAM-1) and
PMPCD31+ with contrast enhancing T1weighted
volumes.
Magnetic resonance imaging protocol
All study subjects underwent brain MRI by a 1.5 T
machine with a standard head coil prior to initiation of
therapy with IFN-b1a (Rebif). The neuroimaging proto-
col consisted of sagittal T1-weighted axial T1- and T2-
and proton density weighted images. All MR studies
were done after infusion of gadolinium diethylenetria-
mine pentaacetic acid (Gd). We used post-contrast T1-
weighted and T2-weighted axial images for assessment
of MS plaques. A neuroradiologist blinded to the sub-
jects’ clinical information, interpreted images and mea-
sured the volume and number of MS lesions. The
second MRI of brain was obtained at month 12 after
initiation of treatment with IFN-b1a.
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Results
Subjects with MS had a mean age of 31 years at study
entry and had a mean duration of the illness of 14
months. There were 14 females and 2 male in this
study. During the course of this study five subjects
developed transient elevation of liver enzymes which
eventually resolved. Apart from this, no other adverse
events occurred as a result of IFN-b1a treatment. Dur-
ing this study we assessed the PMP profiles in MS
patients pre- and post treatment with IFN-b1a (Rebif)
and found that several but not all classes of plasma
endothelial microparticles were altered in MS patients
following treatment over 12 months. All data are
reported as means ± standard error.
CD31
Plasma levels of CD31+ (PECAM-1+) microparticles/ul
were reduced from a baseline level of 400 ± 138/ul at t
= 0 to 167 ± 68/ul at 3 months, and 190 ± 74/ul at 6
months (not statistically significant). Data only reached
statistical significance at 12 months when PMPCD31+
were 98 ± 32/ul (Figure 1, * = p < 0.05). This may
reflect individual variations in patient’s responsiveness
to treatment with IFN-b1a which did not become uni-
form enough to reach statistical significance until the
12th month of treatment. However, comparison of
plasma levels of PMPCD31+ at baseline versus one year
of treatment with IFN-b1a indicates that this marker
shows a significant difference in the quantity of shed
PMP into plasma.
CD146
CD146 also known as melanoma cell adhesion molecule
(Mel-CAM) or cell surface glycoprotein ‘MUC18’ [9]
was marginally statistically altered by IFN-b1a treatment
(p = 0.0511) (Figure 2). After 3 months of IFN-b1a ther-
apy PMPCD146+/ul were reduced from a baseline level
(t = 0) of 10.6 ± 1.8/ul, to 4.4 ± 1.5/ul at 3 months;
these levels returned to 7.9 ± 1.6/ul by 6 months, and
7.75 ± 1.3/ul at 12 months.
CD54
By comparison CD54+ (ICAM-1+) plasma endothelial
microparticles/ul were reduced from a baseline of 211 ±
62.6/ul at t = 0, to 77.4 ± 18.2/ul at 3 months (* p <
0.05), to 74.7 ± 14.4/ul at 6 months (* p < 0.05) and
52.1 ± 15.2 at 12 months (* p < 0.05) after IFN-b1a
therapy compared to t = 0 (Figure 3), suggesting that
CD54 represents the most sensitive microparticle mar-
ker of disease activity.
We compared the plasma levels of CD31+ PMP with the
volume of contrast enhancing T1-weighted lesions pre-
and post treatment with IFN-b1a in order to detect any
correlations between these two parameters. Figure 4
shows a bimodal graph correlating plasma levels of
PMPCD31+ with the volumes of these lesions. We found
that at 12 months both markers were significantly reduced
by IFN-b1a therapy. Similarly Figure 5 also depicts the
bimodal graph relationship between PMPCD54+ and
volumes of contrast-enhancing T1-weighted lesions. Inter-
estingly the magnitude of the reduction in these PMP pro-
files appears to be similar for both PMPCD54+ and
PMPCD31+ when correlated with the volumes of contrast-
enhancing T1-weighted lesions. We did not find any sig-
nificant correlation between the plasma levels of various
classes of PMP and the volumes of T2-weighted lesions
pre- and post treatment with IFN-b1a.
Figure 1 CD31. Levels of CD31+ (PECAM-1) microparticles were
reduced at 3 and 6 months after IFN-b1a therapy, but did not reach
statistical significance until 12 months (* = p < 0.05).
Figure 2 CD146. Levels of CD146+ microparticles were marginally
statistically significantly reduced after IFN-b1a therapy (p = 0.051).
After 3 months of IFN-b1a therapy, CD146+ MPs appeared reduced;
however these levels rebounded by 6 and at 12 months.
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Discussion
High dose high frequency IFN-b1a is an FDA-approved
treatment for MS which reduces annual relapse rate and
improves brain MRI findings. The therapeutic benefits
from IFN-b1a have been attributed to may involve
effects on immune cells elevation of IL-10 and reduced
synthesis of Th1 cytokines endothelial cell adhesion
molecules MMPs resulting in lower leukocyte penetra-
tion of the CNS parenchyma, antigen presentation by
microglia. We observed a decline in the plasma levels of
CD31+ microparticles following treatment of MS
patients with IFN-b1a. The plasma levels of PMPCD31+
were found to be statistically reduced by IFN-b1a ther-
apy at 3, 6 and 12 months. Because these studies were
performed with single staining protocols we cannot
specifically designate these particles as ‘endothelial’, and
these must be considered to be a mixture of platelet and
endothelial derived microparticles. CD31/PECAM-1 is
known to mediate the transendothelial migration of leu-
kocytes [10] in cytokine independent migration. There-
fore, shedding of CD31 in microparticles, may represent
an adaptive response aimed at limiting availability of
CD31 on the endothelial, platelet or leukocyte mem-
branes or alternatively may be another factor which
facilitates transendothelial migration of the activated
leukocytes. Therefore, a decrease in shedding of
PMPCD31+ into plasma following treatment with IFN-
b1b may indicate a lessened interaction between acti-
vated leukocytes and inflamed underlying endothelium,
which in turn translates into stabilization of the blood
brain barrier and decrease in the number of contrast-
enhancing T1-weighted lesions on brain MRI [3]; [11].
In addition, so-called ‘insoluble’ pools of CD31 found
on microparticles may function as antagonists of leuko-
cyte-bound CD31/PECAM-1 which functionally limits
CD31 access, leading to reduced binding and
transmigration.
Turning to another endothelial marker, PMPCD146+,
we observed the effect of treatment of IFN-b1a on the
plasma levels of this biological marker. CD146 is abun-
dantly expressed on the surface of brain endothelial
cells where it may act as a specific functional ligand for
Th17 cells [12]. CD146 is also expressed on the surface
of a subpopulation of activated T-cells [13] and med-
iates lymphocyte-endothelial adhesion. CD146+ micro-
particles were nearly statistically significantly reduced
over 12 months of therapy with IFN-b1a. This change
in CD146+ microparticle expression appeared at 3
months of therapy, and was not observed at 6 or 12
months. CD146, is also known as MUC18, which is
Figure 3 CD54 . By comparison, CD54+ (ICAM-1+) plasma
microparticles were statistically significantly reduced (*, p < 0.05) at
3, 6 and 12 months after IFN-b1a therapy compared to t = 0.
Figure 4 Correlation between CD31+ EMP and T1 weighted
MRI volumes shows that at 12 months both markers were
significantly reduced by IFN-b1a therapy compared to t = 0.
Figure 5 Correlation between CD54+ EMP and T1 weighted
MRI volumes shows that at 12 months both markers were
significantly reduced by IFN-b1a therapy compared to t = 0.
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considered to be a marker of endothelial cells, however
it can also be found on a subset of T- and B-lympho-
cyte, NK cells [14], pericytes [15] and circulating
endothelial cells [16]. Plasma levels of endothelial
derived ‘soluble’ CD146 were inversely correlated with
congestive heart failure [17], it is not clear whether how
transient reductions in CD146 PMPs might be inter-
preted. Plasma levels of PMPCD146+ cannot yet predict a
long term stabilizing effect of IFN-b1a on cerebral
endothelial cells.
During the course of this prospective study, we also
assessed the plasma levels of PMPCD54+ prior to treat-
ment with IFN-b1a and at timed intervals (3, 6 and 12
months) after treatment. PMPCD54+ appears to mainly
represent endothelial microparticles-derived ICAM-1
(CD54), but ICAM-1 can also be expressed by macro-
phages and T-cells. CD54 is constitutively expressed
on the surface of endothelial cells [19], and its’ expres-
sion is significantly upregulated by Th1 cytokines
(TNF-a, IL-1b, IFN-g) which are known to be elevated
during MS exacerbations [19]; [20]. While some stu-
dies have shown elevation of soluble forms of ICAM-1
(CD54) during active MS disease, [21] our study shows
that levels of insoluble microparticles bearing CD54 in
MS disease are significantly reduced by IFN-b1a ther-
apy at 3, 6 and 12 months. In addition, previously Jy
et al. [6] demonstrated that PMPCD54+ formed conju-
gates with monocytes and facilitated their migration
through the endothelial cells monolayers and may
represent an important mechanism supporting the
penetration of immune cells into the CNS parenchyma
in MS.
The correlation of plasma levels of PMPCD31+ and
volumes of contrast-enhancing T1-weighted lesions on
brain MRI is presented as a bimodal graph in Figure 4.
We found that at 12 months both markers (PMPCD31+
and T1-weighted volumes) were significantly reduced by
IFN-b1a therapy. Similarly, Figure 5 also depicts the
bimodal graph relationship between PMPCD54+ and
volumes of contrast-enhancing T1-weighted lesion on
brain MR images. Interestingly, when plotted in this
manner, the magnitude of the reduction in these pro-
files appears to be similar for both PMPCD31+ and
PMPCD54+ with volumes of the contrast-enhancing T1-
weighted lesions. Whether and how these parameters
are mechanistically linked to therapeutic benefit of IFN-
b1a in MS is not clear but lower CD54 appears to
reflect decreased endothelial activation. Because
endothelial CD31/PECAM-1 is not as dramatically
altered by exposure Th1 cytokines, as CD54 is for
example [22], diminished CD31 levels suggest stabiliza-
tion of membrane integrity and reduced platelet activa-
tion both of which could contribute to therapeutic
benefit in MS.
Conclusions
Collectively, the results of our study lend support to the
concept that administration of IFN-b1a to MS patients
is associated with stabilization of the cerebral endothe-
lial cells. This is reflected by concurrent decreases in the
plasma levels of both PMPCD31+ and PMPCD54+ as well
as volumes of contrast-enhancing T1-weighted lesions.
We recommend that, at least during the early stages MS
pathogenesis, measurement of certain sub-populations
of plasma endothelial microparticles may serve as a reli-
able biological marker for disease activity and response
to treatment with beta-interferons.
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